Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data (Q33392997)

26 July 2017

title

Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data (English)

1 reference

26 July 2017

1 reference

Makiko Kusama

1

1 reference

26 July 2017

Kazuya Maeda

2

1 reference

26 July 2017

Koji Chiba

3

1 reference

26 July 2017

Akinori Aoyama

4

1 reference

26 July 2017

Yuichi Sugiyama

5

1 reference

26 July 2017

publication date

12 December 2008

1 reference

26 July 2017

published in

Pharmaceutical Research

1 reference

26 July 2017

volume

26

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

822-835

1 reference

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-008-9781-2

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites

21 January 2018

1 reference

12 December 2020

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers

1 reference

12 December 2020

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members

1 reference

12 December 2020

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro

1 reference

12 December 2020

Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity

1 reference

12 December 2020

Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes

1 reference

12 December 2020

ADMET in silico modelling: towards prediction paradise?

1 reference

12 December 2020

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes

1 reference

12 December 2020

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

1 reference

12 December 2020

Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

1 reference

12 December 2020

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase

1 reference

12 December 2020

Differential activation of CYP2C9 variants by dapsone

1 reference

12 December 2020

In vitro-in vivo correlation of hepatobiliary drug clearance in humans.

1 reference

12 December 2020

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

12 December 2020

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

1 reference

12 December 2020

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

1 reference

12 December 2020

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide

1 reference

12 December 2020

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

1 reference

12 December 2020

Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure

1 reference

12 December 2020

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

1 reference

12 December 2020

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

1 reference

12 December 2020

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example

1 reference

12 December 2020

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

1 reference

12 December 2020

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects

1 reference

12 December 2020

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

1 reference

12 December 2020

Clinical pharmacokinetics of anticonvulsants

1 reference

12 December 2020

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Allelic and functional variability of cytochrome P4502C9.

1 reference

12 December 2020

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

1 reference

12 December 2020

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

1 reference

12 December 2020

A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology

1 reference

12 December 2020

Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism

1 reference

12 December 2020

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

1 reference

12 December 2020

Pharmacokinetics of phenprocoumon

1 reference

12 December 2020

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes

1 reference

12 December 2020

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

1 reference

12 December 2020

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

1 reference

12 December 2020

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

1 reference

12 December 2020

Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor

1 reference

12 December 2020

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

1 reference

12 December 2020

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

1 reference

12 December 2020

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

1 reference

12 December 2020

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

1 reference

12 December 2020

Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices

1 reference

12 December 2020

The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4

1 reference

12 December 2020

Role of CYP2C9 polymorphism in losartan oxidation

1 reference

12 December 2020

Disposition of flurbiprofen in man: influence of stereochemistry and age

1 reference

12 December 2020

Metabolic fate of phenprocoumon in humans

1 reference

12 December 2020

Pharmacogenetics of tolbutamide metabolism in humans

1 reference

12 December 2020

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

12 December 2020

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application

1 reference

12 December 2020

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

1 reference

12 December 2020

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

1 reference

12 December 2020

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

1 reference

12 December 2020

No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3.

1 reference

12 December 2020

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide

1 reference

12 December 2020

Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes

1 reference

12 December 2020

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

12 December 2020

Predicting in vivo drug interactions from in vitro drug discovery data

1 reference

12 December 2020

Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.

1 reference

12 December 2020

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

12 December 2020

Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication

1 reference

12 December 2020

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

12 December 2020

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

1 reference

12 December 2020

Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles

1 reference

12 December 2020

Bioavailability of diclofenac potassium at low doses

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans

1 reference

12 December 2020

Biotransformation of Diclofenac Sodium (Voltaren®) in Animals and in Man.: II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile

1 reference

12 December 2020

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

12 December 2020

Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments

1 reference

12 December 2020

Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms

1 reference

12 December 2020

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

12 December 2020

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

1 reference

12 December 2020

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

1 reference

12 December 2020

Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport

1 reference

12 December 2020

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

12 December 2020

Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide

1 reference

12 December 2020

Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion.

1 reference

12 December 2020

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

1 reference

12 December 2020

Bioavailability of phenytoin on single and multiple oral doses of two dosage forms in normal subjects

1 reference

12 December 2020

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

1 reference

12 December 2020

Genetic analysis of the human cytochrome P450 CYP2C9 locus

1 reference

12 December 2020

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

1 reference

12 December 2020

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo

1 reference

12 December 2020

Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac

1 reference

12 December 2020

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

1 reference

12 December 2020

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

12 December 2020

Pharmacogenetics of warfarin elimination and its clinical implications

1 reference

12 December 2020

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

1 reference

12 December 2020

Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking C

1 reference

12 December 2020

10.1007/S11095-008-9781-2

Identifiers

DOI

1 reference

26 July 2017

1 reference